CN115304656A - 一种特异性激活细胞泛凋亡途径的囊泡药物构建及应用 - Google Patents
一种特异性激活细胞泛凋亡途径的囊泡药物构建及应用 Download PDFInfo
- Publication number
- CN115304656A CN115304656A CN202210708212.XA CN202210708212A CN115304656A CN 115304656 A CN115304656 A CN 115304656A CN 202210708212 A CN202210708212 A CN 202210708212A CN 115304656 A CN115304656 A CN 115304656A
- Authority
- CN
- China
- Prior art keywords
- dna
- exosome
- apoptosis
- solution
- liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000006907 apoptotic process Effects 0.000 title claims abstract description 46
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 230000037361 pathway Effects 0.000 title claims abstract description 15
- 230000003213 activating effect Effects 0.000 title claims abstract description 12
- 238000010276 construction Methods 0.000 title claims description 6
- 210000001808 exosome Anatomy 0.000 claims abstract description 76
- 210000004027 cell Anatomy 0.000 claims abstract description 45
- 239000002502 liposome Substances 0.000 claims abstract description 44
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 108020004414 DNA Proteins 0.000 claims abstract description 20
- 108091027569 Z-DNA Proteins 0.000 claims abstract 14
- 230000008685 targeting Effects 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 13
- 239000012074 organic phase Substances 0.000 claims description 13
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical class [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 12
- 108020001507 fusion proteins Proteins 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 238000011068 loading method Methods 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- 239000008346 aqueous phase Substances 0.000 claims description 9
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Inorganic materials Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 9
- 239000012071 phase Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000005775 apoptotic pathway Effects 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000012228 culture supernatant Substances 0.000 claims description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 239000004017 serum-free culture medium Substances 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 238000005893 bromination reaction Methods 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims 1
- 238000009210 therapy by ultrasound Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 3
- 230000012202 endocytosis Effects 0.000 abstract description 2
- 239000000411 inducer Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 24
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 description 10
- 102100025096 Mesothelin Human genes 0.000 description 10
- 102100032530 Glypican-3 Human genes 0.000 description 7
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 102000004091 Caspase-8 Human genes 0.000 description 6
- 108090000538 Caspase-8 Proteins 0.000 description 6
- 101001011663 Homo sapiens Mixed lineage kinase domain-like protein Proteins 0.000 description 6
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 102100035904 Caspase-1 Human genes 0.000 description 5
- 108090000426 Caspase-1 Proteins 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 230000001338 necrotic effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000003782 apoptosis assay Methods 0.000 description 4
- 230000005522 programmed cell death Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 208000004852 Lung Injury Diseases 0.000 description 3
- 206010069363 Traumatic lung injury Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 231100000515 lung injury Toxicity 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000021597 necroptosis Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- NOIRDLRUNWIUMX-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;6-amino-1h-pyrimidin-2-one Chemical compound NC=1C=CNC(=O)N=1.O=C1NC(N)=NC2=C1NC=N2 NOIRDLRUNWIUMX-UHFFFAOYSA-N 0.000 description 2
- 101000964436 Homo sapiens Z-DNA-binding protein 1 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100037924 Insulin-like growth factor 2 mRNA-binding protein 1 Human genes 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 101000599776 Rattus norvegicus Insulin-like growth factor 2 mRNA-binding protein 1 Proteins 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000005337 ground glass Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000047934 Caspase-3/7 Human genes 0.000 description 1
- 108700037887 Caspase-3/7 Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000006010 pyroptosis Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及生物医药领域,具体是一种用于特异性激活细胞泛凋亡途径的囊泡类药物及其制备方法和应用,其中的细胞凋亡诱导剂为体外制备的Z构型DNA,通过脂质体或外泌体包裹后,可以通过细胞内吞将Z‑DNA运输至细胞内,从而诱导细胞发生泛凋亡。本发明可以作为泛凋亡研究的标准化药物,或用于肿瘤治疗。
Description
技术领域
本发明涉及生物医药技术领域,具体地说,是一种特异性激活细胞泛凋亡途径的囊泡药物构建及应用。
背景技术
程序性细胞死亡介导了多种病理、生理过程的发生,包括胚胎发育、组织稳态维持和宿主对病原体的免疫防御。程序性细胞死亡由不同的分子信号通路控制,其参与机体中不需要的细胞或异常细胞的清除。目前的观点认为因细胞凋亡(apoptosis)而死亡的细胞是非免疫原性的,而坏死性凋亡(necroptosis)和细胞焦亡(pyroptosis)会驱动免疫反应。
近期研究发现,不同形式程序性细胞死亡具有不同的分子机制和死亡方式,各种形式的程序性细胞死亡途径之间又存在着明显的串扰:细胞凋亡和坏死性凋亡通路通过caspase8的活性紧密相连,caspase8活化后不仅会激活下游的caspase3/7促进凋亡发生,亦可以通过介导MLKL磷酸化可以促进坏死性凋亡的信号传导;坏死性凋亡和细胞焦亡都具有相同的溶解性和潜在的炎症形态,NLRP3炎症小体活化可同时引发Caspase1与MLKL活化,引发坏死性凋亡和细胞焦亡。细胞焦亡、细胞凋亡和坏死性凋亡在感染性疾病中引起的组织损伤中常共同发生介导组织损伤,被称为泛凋亡途径(PANoptosis)。然而,除利用高剂量病毒感染引发泛凋亡外,目前尚缺乏稳定性高、可重复性强的诱导细胞泛凋亡手段。这严重制约了研究泛凋亡发生机制、以及利用泛凋亡途径进行肿瘤等疾病的治疗。
目前认为,泛凋亡是由AIM2(absent in melanoma 2)、Z-DNA结合蛋白(Z-DNAbanding protain1,ZBP1)等蛋白形成泛凋亡蛋白复合体(PANoptosome)诱导发生。ZBP1蛋白含有Zα结构域,可以特异性识别左旋双股螺旋Z型DNA(Z-DNA),激活细胞泛凋亡发生。Z-DNA是1979年Rich等人在X射线下发现,含有丰富的鸟嘌呤-胞嘧啶(G-C)交替序列,在炎症、缺氧、微生物感染、肿瘤等疾病可引起Z-DNA在细胞内大量聚集,与细胞浆内ZBP1结合,激活细胞发生泛凋亡。虽然Z-DNA可以激活泛凋亡发生,但Z-DNA处于高能状态而不稳定,如何制备稳定的Z-DNA药物是限制其应用的难点。
使用Z-DNA诱导泛凋亡的另一瓶颈是如何实现Z-DNA的胞内递送。脂质体是双亲性脂分子在水相中进行自组装形成的双层膜脂小泡,可以将特定物质(药物或基因片段等)包埋在脂质体内部,形成特定的运输系统。外泌体是细胞分泌产生的一种直径在30-200nm的微小囊泡,其细胞膜通常组成型表达PDGFR、CD81、CD9等膜蛋白。利用这一特性可将靶向细胞的多肽或抗体片段与上述分子组成嵌合分子,使工程化细胞分泌的外泌体具有高度的靶向性,从而实现Z-DNA的靶向运输。
发明内容
本发明的目的在于提供一种包裹有Z-DNA片段的脂质体或精准靶向外泌体及其制备方法,由此制备的囊泡药物可以特异性激活细胞泛凋亡途径(PANoptosis)。
本发明的第一方面,提供一种稳定的Z-DNA制备方法,包括以下步骤:
a)合成50-200bp的poly(dG-dC);将poly(dG-dC)溶解于pH=7.5-8.0的0.5mMEDTA·3.5M NaCl溶液,后将pH调制6.5;
在本发明的一个优选的实施方式中,步骤a中合成100-150bp的poly(dG-dC)。
b)制备饱和溴水:在磨口玻璃塞瓶中加入1L ddH2O与16mL单质溴,置于摇床以250rpm室温震荡混匀2个小时,静置后吸取上层橙红色溶液,为饱和溴水;
c)饱和溴水以1~2倍体积逐滴加入poly(dG-dC)溶液,混合后室温下轻柔颠倒混匀30分钟,使DNA发生溴化反应;
在本发明的一个优选的实施方式中,步骤c中饱和溴水和poly(dG-dC)溶液以1.3:1.0的比例进行混合。
d)在反应液中加入10%体积的四氯化碳,振荡混匀萃取反应液中剩余的溴单质,吸取上层水相,即获得含有Z-DNA的溶液;
e)Z-DNA溶液通过超滤浓缩,Z-DNA含量使用dot-blot进行鉴定。
本发明的第二方面,提供一种采用如上所述的制备方法制备得到的稳定的Z-DNA。
本发明的第三方面,提供一种用于特异性激活细胞泛凋亡的脂质体的制备方法,包括以下步骤:
(A)配制脂质材料的乙醇溶液(有机相):称取磷脂酰胆碱10mg~30mg、胆固醇1mg~10mg,DOTAP 5mg~50mg,溶于10mL无水乙醇;
在本发明的一个优选的实施方式中,步骤A中使用磷脂酰胆碱30mg、胆固醇10mg、DOTAP 10mg溶于10mL无水乙醇。
(B)含有Z-DNA的水相:如上所述的超滤浓缩后的Z-DNA溶液使用0.5MPBS稀释至1~5ng/μL;
在本发明的一个优选的实施方式中,步骤B中使用2ng/μL Z-DNA稀释液作为水相。
(C)将装有有机相的1ml注射器置于微流控泵1通道固定,将装有水相的1mL注射器置于微流控泵2通道固定。按照水相:有机相的流速比2~5:1微流控参数进行设置。
在本发明的一个优选的实施方式中,为了获得直径在100~200nm范围的脂质体,步骤C中使用水相:有机相的流速比为3:1。
(D)启动微流控系统,使得有机相和水相在芯片中混合,弃掉初始10%流出液,收集其余流出液,使用NTA法表征脂质体。
本发明的第四方面,提供一种采用如上制备方法制备得到的用于特异性激活细胞泛凋亡的脂质体。
本发明的第五方面,提供一种用于诱导细胞发生泛凋亡途径(PANoptosis)的靶向外泌体的制备方法,包括以下步骤:
步骤一:将人工嵌合蛋白的编码基因克隆至pcDNA3.1质粒,转染293T细胞,使用无血清培养基培养48小时,收集培养上清,26000g离心2小时收集外泌体;
步骤二:Z-DNA加载外泌体:将外泌体与如上所述的Z-DNA溶液按照质量比10:1进行混合,使用超声法进行装载,设置超声参数为60Hz超声30s,暂停30s,循环3次;在超声结束后放置在37℃的摇床,50rpm孵育1小时,帮助外泌体恢复膜结构;26000g离心2小时收集外泌体;获得加载有人工Z-DNA的靶向外泌体。
其中,所述的靶向外泌体利用外泌体组成型表达蛋白与多肽或抗体序列嵌合构成,其基本构成为:信号肽—靶向蛋白—跨膜序列;
进一步的,为了实现外泌体对αv integrin阳性细胞的精准靶向,工程化外泌体组装了编码基因序列如SEQ ID NO.1所示的人工嵌合蛋白。
进一步的,为了实现外泌体对CD19阳性细胞的精准靶向,工程化外泌体组装了编码基因序列如SEQ ID NO.2所示的人工嵌合蛋白。
进一步的,为了实现外泌体对GPC3阳性细胞的精准靶向,工程化外泌体组装了编码基因序列如SEQ ID NO.3所示的人工嵌合蛋白。
进一步的,为了实现外泌体对MUC1阳性细胞的精准靶向,工程化外泌体组装了编码基因序列如SEQ ID NO.4所示的人工嵌合蛋白。
进一步的,为了实现外泌体对MSLN阳性细胞的精准靶向,工程化外泌体组装了编码基因序列如SEQ ID NO.5所示的人工嵌合蛋白。
进一步的,为了实现外泌体对Claudin18.2阳性细胞的精准靶向,工程化外泌体组装了编码基因序列如SEQ ID NO.6所示的人工嵌合蛋白。
进一步的,为了实现外泌体对PDL1阳性细胞的精准靶向,工程化外泌体组装了编码基因序列如SEQ ID NO.7所示的人工嵌合蛋白。
进一步的,为了实现外泌体对NKG2DL阳性细胞的精准靶向,工程化外泌体组装了编码基因序列如SEQ ID NO.8所示的人工嵌合蛋白。
进一步的,为了实现外泌体对GD2阳性细胞的精准靶向,工程化外泌体组装了编码基因序列如SEQ ID NO.9所示的人工嵌合蛋白。
本发明的第六方面,提供一种采用如上制备方法制备得到的用于诱导细胞发生泛凋亡途径(PANoptosis)的靶向外泌体。
本发明的第七方面,提供如上所述的Z-DNA、脂质体或靶向外泌体在制备诱导细胞发生泛凋亡途径(PANoptosis)的药物中的应用。
本发明的第八方面,提供如上所述的Z-DNA、脂质体或靶向外泌体在构建细胞泛凋亡模型中的应用。
本发明的第九方面,提供如上所述的Z-DNA、脂质体或靶向外泌体在制备抗肿瘤药物中的应用。
进一步的,所述的肿瘤包括但不限于表达特定肿瘤相关抗原的肝癌、胰腺癌、胃癌、结直肠癌、肺癌、乳腺癌、神经母细胞瘤、胶质瘤、子宫内膜癌、宫颈癌、卵巢癌、胆管癌、淋巴瘤、食管癌、鼻咽癌等。
本发明优点在于:
1、本发明提供一种用于特异性激活细胞泛凋亡途径的囊泡类药物,细胞凋亡诱导剂为体外制备的Z构型DNA,通过脂质体或外泌体包裹后,可以通过细胞内吞将Z-DNA运输至细胞内,从而诱导细胞发生泛凋亡。
2、本发明提供的用于特异性激活细胞泛凋亡的脂质体或外泌体的制备方法,可以在体内及体外稳定激活细胞泛凋亡通路,是一种新型构建细胞泛凋亡模型的药物,可以作为泛凋亡研究的标准化药物,用于细胞泛凋亡相关研究。
3、本发明提供的用于特异性激活细胞泛凋亡的靶向性工程外泌体的制备方法,可以在体内诱导特定细胞群体的发生泛凋亡,可用于肿瘤的治疗。
附图说明
图1是利用微流控芯片制备脂质体的示意图
图2是本发明实施例的Z-DNA脂质体的制备流程示意图。
图3是本发明实施例中应用NTA与电镜对Z-DNA脂质体进行表征。
图4是Z-DNA脂质体置于4℃避光保存,每5日取样进行dot-blot检测DNA含量。
图5是Western-blot检测Z-DNA脂质体对Caspase1、Caspase8与MLKL活化。
图6是使用GPC3靶向外泌体负载Z-DNA后杀伤GPC3阳性的HepG2细胞后,测定上清乳酸脱氢酶含量
图7是使用MSLN靶向外泌体负载Z-DNA后杀伤MSLN阳性的BXPC3细胞后,测定上清乳酸脱氢酶含量
图8是使用Z-DNA脂质体滴鼻小鼠后建立的肺损伤模型。A图为肺的HE病理检测,B图为小鼠给药后生存期。
具体实施方式
下面结合实施例对本发明提供的具体实施方式作详细说明。本领域技术人员应当理解,下面所具体描述的内容是说明性的而非限制性的,不应以此限制本发明的保护范围。
除非另有描述,本发明的实施将采用分子生物学、微生物学、重组DNA和免疫学的常规技术,这些均是本领域技术人员所知的。这些技术在下列文献中有完整的描述:例如,Sambrook《分子克隆实验指南》第2版(1989);《DNA克隆》第I和II卷(D.N.Glover编辑1985);《寡核苷酸合成》(M.J.Gait编辑,1984);《核酸杂交》(B.D.Hames和S.J.Higgins编辑.1984);《蛋白质纯化:原理和实践》第2版(Springer-Verlag,N.Y.),以及《实验免疫学手册》I-IV卷(D.C.Weir和C.C.Blackwell编辑1986)。或者,可按照试剂生产商所提供的说明书进行。
除非另外说明,否则百分比和份数按重量计算。除非另行定义,文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外,任何与所记载内容相似或均等的方法及材料皆可应用于本发明中。文中所述的较佳实施方法与材料仅作示范之用。
实施例1:人工Z-DNA溶液的制备
实验方法:①合成100-150bp的poly(dG-dC);将poly(dG-dC)溶解于pH=7.5-8.0的0.5mM EDTA·3.5M NaCl溶液,后将pH调制6.5。②制备饱和溴水:在磨口玻璃塞瓶中加入1L ddH2O与16mL单质溴,置于摇床以250rpm室温震荡混匀2个小时,静置后吸取上层橙红色溶液,为饱和溴水。③饱和溴水以1.3:1.0倍体积逐滴加入poly(dG-dC)溶液进行混合;混合后室温下轻柔颠倒混匀30分钟,使DNA发生溴化反应。④在反应液中加入10%体积的四氯化碳,振荡混匀萃取反应液中剩余的溴单质,吸取上层水相,即获得含有Z-DNA的溶液。⑤Z-DNA溶液通过超滤浓缩,Z-DNA含量使用dot-blot进行鉴定。
实施例2:合成含有人工Z-DNA脂质体的制备
实验方法:①配制脂质材料的乙醇溶液(有机相):称取磷脂酰胆碱30mg、胆固醇10mg、DOTAP 10mg,溶于10mL无水乙醇。②含有Z-DNA的溶液(水相):实施例1中超滤浓缩后的Z-DNA溶液使用0.5M PBS稀释至2ng/μL。③将装有有机相的1ml注射器置于微流控泵1通道固定,将装有水相的1mL注射器置于微流控泵2通道固定。按照水相:有机相的流速比3:1微流控参数进行设置(图1)。④启动微流控系统,使得有机相和水相在芯片中混合,弃掉初始10%流出液,收集其余流出液,使用NTA法表征脂质体。
图2是本发明实施例的人工脂质体的制备流程示意图。
实施例3:基于人工合成的包含Z-DNA的脂质体的表征和稳定性检测实验方法:将实施例2制备好的Z-DNA脂质体置于4℃避光保存,每5日取样进行dot-blot检测,检测DNA含量。
实验结果:应用NTA与电镜对制备的Z-DNA脂质体表征进行检测。图3是本发明实施例中应用NTA与电镜对Z-DNA脂质体进行表征,结果表明Z-DNA脂质体直径大小为80-200nm之间,大部分颗粒直径为150nm。Z-DNA脂质体置于4℃避光保存,每5日取样进行dot-blot检测DNA含量,结果表明Z-DNA脂质体在该条件下可稳定保存30天以上,观察期内Z-DNA含量未发生显著改变(图4)。
实施例4:基于人工合成的包含Z-DNA的脂质体对肺泡细胞泛凋亡途径的活化作用
实验方法:Z-DNA脂质体诱导Lenti-X-293T细胞。Western-blot检测Z-DNA脂质体对Caspase1、Caspase8与MLKL活化。
实验结果:图5是Western-blot检测Z-DNA脂质体对泛凋亡三条通路Caspase1、Caspase8与MLKL活化。图5结果显示,本发明制备的Z-DNA脂质体可诱导细胞焦亡(Caspase1通路)、细胞凋亡(Caspase8通路)和坏死性凋亡(MLKL通路)的信号活化。
实施例5:包覆有人工Z-DNA的靶向GPC3外泌体的制备及其对HepG2肿瘤细胞的杀伤活性
实验方法:
第一步,包覆有人工Z-DNA的靶向GPC3外泌体的制备
①将SEQ ID NO.3所示的基因序列克隆至pcDNA3.1质粒,转染293T细胞,使用无血清培养基培养48小时,收集培养上清,26000g离心2小时收集外泌体。
②Z-DNA加载外泌体:将外泌体与实施例1中Z-DNA溶液按照质量比10:1进行混合,使用超声法进行装载,设置超声参数为60Hz超声30s,暂停30s,循环3次。在超声结束后放置在37℃的摇床,50rpm孵育1小时,帮助外泌体恢复膜结构。26000g离心2小时收集外泌体。获得包覆有人工Z-DNA的靶向GPC3的外泌体。
第二步,包覆Z-DNA的GPC3靶向外泌体对GPC3阳性的HepG2肿瘤细胞的体外杀伤效率研究。将包覆有Z-DNA外泌体按颗粒比5:1与HepG2肿瘤细胞共培养,在共培养4小时、8小时、12小时后使用LDH试剂盒检测培养上清中LDH含量。
实验结果:如图6所示,包覆Z-DNA的GPC3靶向外泌体可以有效诱导GPC3阳性的肝癌细胞凋亡。
实施例6:包覆有人工Z-DNA的靶向MSLN外泌体的制备及其对BXPC3肿瘤细胞的杀伤活性
实验方法:
第一步,包覆有人工Z-DNA的靶向MSLN外泌体的制备
①将SEQ ID NO.5所示的基因序列克隆至pcDNA3.1质粒,转染293T细胞,使用无血清培养基培养48小时,收集培养上清,26000g离心2小时收集外泌体。
②Z-DNA加载外泌体:将外泌体与实施例1中Z-DNA溶液按照质量比10:1进行混合,使用超声法进行装载,设置超声参数为60Hz超声30s,暂停30s,循环3次。在超声结束后放置在37℃的摇床,50rpm孵育1小时,帮助外泌体恢复膜结构。26000g离心2小时收集外泌体。获得包覆有人工Z-DNA的靶向MSLN的外泌体。
第二步,包覆Z-DNA的MSLN靶向外泌体对MSLN阳性的BXPC3肿瘤细胞的体外杀伤效率研究。将包覆有Z-DNA外泌体按颗粒比5:1与BXPC3肿瘤细胞共培养,在共培养4小时、8小时、12小时后使用LDH试剂盒检测培养上清中LDH含量。
实验结果:如图7所示,包覆Z-DNA的MSLN靶向外泌体可以有效诱导MSLN阳性的胰腺癌细胞凋亡。
实施例7:Z-DNA脂质体诱导小鼠肺损伤模型
实验方法:
将Z-DNA脂质体母液稀释至1×109个/mL,取100μL滴鼻吸入,对照组吸入等量的空载脂质体。HE染色检测肺部损伤水平,同时观察小鼠生存期。
实验结果:
Z-DNA脂质体吸入后,诱发肺泡细胞损伤并继发炎症反应,出现典型的肺实质变;肺泡内充满纤维素样渗出及红细胞、淋巴细胞浸润,肺泡间隔增宽(图8A)。吸入Z-DNA的小鼠在3天内完全死亡(图8B)。
以上已对本发明创造的较佳实施例进行了具体说明,但本发明创造并不限于所述实施例,熟悉本领域的技术人员在不违背本发明创造精神的前提下还可做出种种的等同的变型或替换,这些等同的变型或替换均包含在本申请权利要求所限定的范围内。
序列表
<110> 中国人民解放军海军军医大学第一附属医院
<120> 一种特异性激活细胞泛凋亡途径的囊泡药物构建及应用
<130> /
<160> 9
<170> SIPOSequenceListing 1.0
<210> 1
<211> 207
<212> DNA
<213> 人工序列(Artificial)
<400> 1
atgagattgc ctggcgcaat gcccgctttg gccttgaaag gagaactgct ccttctgtcc 60
cttctgctct tgcttgagcc tcagatcagc cagggatgca gaggggacaa gggcccagac 120
tgcgttgtga tcagcgcaat tctcgcactg gtcgtgctga caatcatctc cctgattatt 180
ctgattatgc tgtggcagaa gaaacct 207
<210> 2
<211> 891
<212> DNA
<213> 人工序列(Artificial)
<400> 2
atgagattgc caggagctat gcctgccctt gcactgaagg gagaacttct gctgttgagc 60
ctgttgttgc tcctggagcc ccagatttcc cagggcgaca tccagatgac ccagtcccca 120
tcatcactct ctgcctctgt gggcgaccga gtgacaatca cttgtcgggc cagcgacatt 180
tcaaaatacc tgaattggta tcagcagaag cccggcaagg ccccaaaact tctgatctat 240
cacacttctc ggctgcactc cggagttcct tcaaggttct caggaagcgg ttctgggacg 300
gatttcaccc tcaccatcag cagcttgccc gaggactttg cgacatacta ttgccagggc 360
aatactctgc cctatacttt tggtgggggg acaaaagttg aaattaaagg aggtggaggt 420
tctggaggag ggggcagtgg tggaggagga agtgaggtgc agctcgtgga aagtggaggc 480
ggtttggtgc aacctggagg atctctgcga ctttcctgcg ctgcttcagg tgtaagtctg 540
ccagattatg gcgtatcctg ggtgaggcaa gcccctggaa aaggattgga gtgggtttct 600
gttatctggg gctcagagac cacttactac aattccgccc tgaagagccg ctttaccata 660
tcacgcgaca acagcaaaaa taccctttac ctgatgaatt ctttgagggc tgaagatacc 720
gcggtgtatt attgcgctaa gcactactat tacgggggaa gctacgccat ggattactgg 780
ggagggactc tggttactgt gtccagcgtc gttatctctg ccatcctggc actcgtagtc 840
ctcaccatca tctccctgat cattttgatt atgctgtggc aaaaaaagcc a 891
<210> 3
<211> 906
<212> DNA
<213> 人工序列(Artificial)
<400> 3
atgagattgc ctggagccat gccagctctt gctctgaaag gagaactgct gcttctgagc 60
ctgctgcttc tgctggagcc tcagatctct cagggtgacg tcgtgatgac tcagtccccc 120
ctctctcttc ctgtgacccc aggggagcca gcaagcatca gttgccgctc ttcccaatcc 180
ctggtccact ccaacgccaa cacttacctt cactggtacc tccagaagcc cggacagtct 240
ccacagctgc tgatctataa ggtgtctaat cggttcagcg gagtgcccga cagattctca 300
gggtcagggt ctggtacgga ttttaccctg aaaatctcac gagttgaagc cgaagatgtg 360
ggggtttatt actgtagcca gaacacccac gtacccccca ctttcggcca gggaacaaag 420
ctcgagataa agggtggtgg aggatccggt ggtggaggtt ctggcggagg aggttctcaa 480
gtgcaacttg ttcagagtgg ggctgaagtg aaaaagcccg gggccagcgt gaaggtgagt 540
tgcaaagcct cagggtacac cttcactgac tacgagatgc attgggtcag acaagcacct 600
ggccagggac ttgaatggat gggcgctctc gaccctaaaa cgggcgacac cgcatattca 660
cagaaattca aaggcagggt gactcttacc gctgacgaaa gtacctcaac cgcctacatg 720
gagctgtcaa gcctccggtc tgaagacacc gcggtctact attgtacccg cttctatagc 780
tacacatact ggggccaggg aactctcgtg acggtgagca gcgtggtcat ctccgcaatc 840
ctcgctttgg tggtcctgac aattatttct ttgatcattc tgatcatgct ctggcagaaa 900
aagccg 906
<210> 4
<211> 909
<212> DNA
<213> 人工序列(Artificial)
<400> 4
atgagattgc ctggcgctat gcctgctttg gcccttaagg gagaactgct cctcctgagt 60
ctgcttctcc tgttggaacc tcagataagc caaggggaag tgcttcagca gtcaggcgca 120
gaactggtca agccaggtgc ctcagtgaag ttgtcctgca ctgccagtgg cgaaaacatc 180
aaggactatt acatgcactg ggtcaagcag cgcacagagc agggccttga atggatcgga 240
cggattgacc cagaggacgg tgagacaaaa tatgccccca aatttggcaa ggctatcatt 300
accgcggata ctagttctaa caccgcctat ctgctgtcat ctcttactag cgaagacact 360
gcagtctact actgcgttca cttctactat ggctacgacg tcggacgagg ctattggggt 420
caaggcacca ccctgacagt gagttctgga ggtggaggaa gtgggggagg aggaagcgga 480
ggaggaggat cagacatcgt tatgtcacag agtcctagtt ctctggcagt ctcagtgggg 540
gagaaggtca ctatgtcttg taaaagttct cagtctctgc tgtacagcag taaccagaaa 600
aactacctgg catggtacca gcaaaagcct ggccaaagcc caaagctgct catttattgg 660
gcgtctacca gggagtctgg cgtgcctgat cgctttaccg gctcagggag tgggaccgat 720
ttcacactca caataagttc agtgaaggca gaggacctcg ccgtttacta ctgccagcag 780
tactactcat acaccttcgg cggtggaaca aaactggaga taaaggttgt gatctccgcc 840
attcttgccc tggtggtgtt gacaatcata tcattgatta tcctgattat gctgtggcag 900
aaaaaaccc 909
<210> 5
<211> 924
<212> DNA
<213> 人工序列(Artificial)
<400> 5
atgaggctgc caggagctat gcctgcattg gcactgaaag gagaactcct gcttctgtca 60
cttcttttgc tccttgagcc acagatttct cagggcgacg tggtgatgac gcagactcct 120
gcctcagttt ctgagccagt tggggggacg gtgaccatca agtgtcaggc gtcccagaga 180
attagtagct atctgtcatg gtatcagcag aagccaggac agcggcccaa acttctgatc 240
ttcggggcta gtacccttgc atctggggtt cccagcaggt tcaaaggctc aggctccggt 300
accgagtaca cattgactat ttccgacctg gaatgtgccg atgccgctac ctattactgc 360
cagtcctatg cctactttga ttccaacaat tggcacgctt tcggaggcgg aacagaagtg 420
gttgtgggag gaggtggatc aggaggagga ggatctggcg gtggtggctc acagcagcaa 480
ctggaagagt ccggtggagg cctggtgaag ccagaaggct ccctcaccct cacttgcaaa 540
gcctccgggt ttgatttggg attctacttt tacgcttgtt gggtgcgaca ggcccctgga 600
aaggggttgg aatggatcgc gtgtatctat acggctggca gcggcagcac ctattatgcg 660
tcatgggcca agggacggtt cactatcagc aaagctagct ccaccacggt gacactgcag 720
atgacgagtc tggctgcagc agacacggcc acttatttct gcgcgcgcag tactgcaaat 780
acacggtcta cttattacct gaacctgtgg gggcccggca cattggtgac agtgtcctct 840
gttgtaatta gcgccattct cgcccttgtc gtgctgacta ttatttccct gatcatcctg 900
attatgctgt ggcaaaaaaa gccc 924
<210> 6
<211> 918
<212> DNA
<213> 人工序列(Artificial)
<400> 6
atgaggttgc ccggcgcaat gccagctctt gctttgaaag gagaactgct gttgctgtca 60
ctgctgctgt tgctggagcc ccagatcagc cagggtcagg tacagttgca gcagccaggt 120
gctgaactcg tacgacccgg agcctcagtg aaattgtctt gcaaggccag cggatacaca 180
ttcacgtcat actggatcaa ctgggtgaag cagagaccag gacaggggct cgagtggatt 240
gggaacatct accctagcga ttcctacacc aattacaacc aaaagttcaa ggataaggct 300
accctgaccg ttgacaaatc aagtagcaca gcttacatgc agctgagcag ccctactagt 360
gaggactcag ccgtgtacta ctgtacacgc agttggcgcg gcaacagctt cgattactgg 420
ggacagggta caactttgac cgtgtcaagc ggaggaggtg gatctggcgg tggaggatca 480
ggaggaggag gaagtgacat tgtgatgact cagtctccat ctagcctcac agtgactgcc 540
ggggagaaag tgaccatgtc atgcaaaagc tctcaatcac tcttgaattc tgggaatcag 600
aagaactatt tgacctggta ccagcagaaa ccaggacagc ctcccaagct gttgatatac 660
tgggcttcaa ctcgggaaag cggcgtgccc gatcgcttca caggtagtgg ttcaggaact 720
gatttcacac tgaccatcag ctccgttcag gctgaggatt tggccgtcta ttattgccag 780
aacgactact cttatccttt cacctttggc agcgggacaa agctcgagat caaggtggtg 840
attagcgcta ttctggcttt ggtggtcctg acaattatat cattgatcat tttgatcatg 900
ctgtggcaaa agaagcca 918
<210> 7
<211> 630
<212> DNA
<213> 人工序列(Artificial)
<400> 7
atgagactgc caggtgcaat gccagccttg gccttgaaag gagaactcct cttgttgtcc 60
ctgctgcttc tcctcgagcc acagatttcc caggggccag gttggttttt ggattccccg 120
gacagaccat ggaatccacc gacctttagt ccagcgctgc tggtggtcac tgagggagat 180
aacgccacct tcacatgtag cttctccaat acgtctgaat cctttgtact gaactggtac 240
aggatgtcac cctccaacca gaccgataag ctcgctgcgt ttccagagga tagatcacag 300
ccggggcagg actgcagatt tcgcgtcacc cagcttccta atggacggga ttttcacatg 360
tccgttgtgc gggcaaggag gaatgacagt gggacatact tgtgcggagc catcagcctt 420
gctccaaagg cccagatcaa ggagtccctc agggccgagc tgagagtgac agaacgaaga 480
gccgaggtac ctaccgccca tccttctcct agcccacgac ccgcaggaca attccagacc 540
ctggtggttg ttatttctgc catcttggct ctcgtcgtgc tgacgattat atctctcatc 600
atcctgatta tgctgtggca gaaaaagccg 630
<210> 8
<211> 612
<212> DNA
<213> 人工序列(Artificial)
<400> 8
atgagactcc ctggagctat gccggctctt gctcttaaag gagagctgct gctgctcagt 60
ctgctgctgc tgctggaacc ccagatctca cagggaattt ggtccgccgt ctttctcaac 120
agtctgttta accaagaggt gcaaattccc cttaccgaga gctactgtgg tccgtgcccc 180
aagaactgga tctgctacaa gaacaattgc taccagttct tcgatgagtc caagaattgg 240
tacgaatccc aggcttcctg tatgagccaa aatgccagcc tcttgaaagt gtactcaaag 300
gaggatcaag atctcctgaa gctcgtgaag agttaccact ggatgggctt ggtgcacatc 360
cccactaacg gcagctggca atgggaagac ggatccatat tgtcaccaaa cctgctcacc 420
atcatcgaaa tgcagaaggg tgattgcgca ctctatgcca gtagcttcaa aggctatatc 480
gagaactgtt caacacccaa cacgtatatt tgcatgcaga ggaccgtagt ggtgatctca 540
gccatcttgg cactcgtggt gttgacaatc atcagcctca tcatccttat tatgctgtgg 600
cagaagaaac ca 612
<210> 9
<211> 915
<212> DNA
<213> 人工序列(Artificial)
<400> 9
atgagacttc ccggagcaat gccagcattg gctcttaaag gggagctcct gttgctgtca 60
ctgctgctcc tcctggagcc ccagatcagc caagggcagg tgaagcttca ggaaagcggg 120
ggaggtcttg ttcagccagg tggctccatg aagctctctt gcgtggtcag cgggttcact 180
ttttctaatt actggatgaa ttgggttcgg caaagcccgg agaaggggct ggaatggatc 240
gccgaaattc gactcaagtc aaacaatttt gccaggtact atgcagagtc cgtgaaggga 300
cggttcacta tctccagaga tgattccaag gggtccgtct accttcagat gatcaacctg 360
cgcgccgagg ataccggaat ctattactgc acctcctacg gcaactacgt gggacactac 420
tttgaccact ggggacaagg aacaacggta accgttagtt caggcggagg tggttcagga 480
ggaggaggat ctggaggagg cggatccgat atcgagctca cgcagtctcc taagtttatg 540
agcacaagtg ttggggatag ggtttccgtc acctgtaaag ccagccagaa cgtggacaca 600
aatgtggctt ggtaccagca gaaaccggga caatctccag agccccttct gttcagcgct 660
agttataggt acactggcgt gccagatcgg ttcactggat caggcagcgg aacagatttc 720
acattgacta tttcaaacgt ccagagcgag gatctggctg agtacttctg ccagcaatac 780
aattcctacc cactgacttt tgggggcgga accaagctcg agatcaaacg cgtcgttatt 840
agcgccattc tggctctcgt tgtgctgacc atcatatccc tcattatact gatcatgctc 900
tggcaaaaga agccc 915
Claims (10)
1.一种稳定的Z-DNA制备方法,其特征在于,包括以下步骤:
a)合成50-200bp的poly(dG-dC);将poly(dG-dC)溶解于pH=7.5-8.0的0.5mM EDTA·3.5M NaCl溶液,后将pH调制6.5;
b)制备饱和溴水;
c)饱和溴水以1~2倍体积逐滴加入poly(dG-dC)溶液,混合后室温下轻柔颠倒混匀30分钟,使DNA发生溴化反应;
d)在反应液中加入10%体积的四氯化碳,振荡混匀萃取反应液中剩余的溴单质,吸取上层水相,即获得含有Z-DNA的溶液;
e)Z-DNA溶液通过超滤浓缩,Z-DNA含量使用dot-blot进行鉴定。
2.一种采用如权利要求1所述的制备方法制备得到的稳定的Z-DNA。
3.一种用于特异性激活细胞泛凋亡的脂质体的制备方法,其特征在于,包括以下步骤:
(A)配制脂质材料的乙醇溶液(有机相):称取磷脂酰胆碱10mg~30mg、胆固醇1mg~10mg,DOTAP 5mg~50mg,溶于10mL无水乙醇;
(B)含有Z-DNA的水相:如上所述的超滤浓缩后的Z-DNA溶液使用0.5M PBS稀释至1~5ng/μL;
(C)将装有有机相的1ml注射器置于微流控泵1通道固定,将装有水相的1mL注射器置于微流控泵2通道固定;按照水相:有机相的流速比2~5:1微流控参数进行设置;
(D)启动微流控系统,使得有机相和水相在芯片中混合,弃掉初始10%流出液,收集其余流出液,使用NTA法表征脂质体。
4.一种采用如权利要求3的制备方法制备得到的用于特异性激活细胞泛凋亡的脂质体。
5.一种用于诱导细胞发生泛凋亡途径的靶向外泌体的制备方法,其特征在在于,包括以下步骤:
步骤一:将人工嵌合蛋白的编码基因克隆至pcDNA3.1质粒,转染293T细胞,使用无血清培养基培养48小时,收集培养上清,26000g离心2小时收集外泌体;
步骤二:Z-DNA加载外泌体:将外泌体与如上所述的Z-DNA溶液按照质量比10:1进行混合,使用超声法进行装载,设置超声参数为60Hz超声30s,暂停30s,循环3次;在超声结束后放置在37℃的摇床,50rpm孵育1小时,帮助外泌体恢复膜结构;26000g离心2小时收集外泌体;获得加载有人工Z-DNA的靶向外泌体。
6.根据权利要求5所述的用于诱导细胞发生泛凋亡途径的靶向外泌体的制备方法,其特征在在于,所述的人工嵌合蛋白的编码基因序列如SEQ ID NO.1~SEQ ID NO.9任一所示。
7.一种采用如权利要求5或6所述的制备方法制备得到的用于诱导细胞发生泛凋亡途径的靶向外泌体。
8.如权利要求2所述的Z-DNA、如权利要求4所述的脂质体或如权利要求7所述的靶向外泌体在制备诱导细胞发生泛凋亡途径的药物中的应用。
9.如权利要求2所述的Z-DNA、如权利要求4所述的脂质体或如权利要求7所述的靶向外泌体在构建细胞泛凋亡模型中的应用。
10.如权利要求2所述的Z-DNA、如权利要求4所述的脂质体或如权利要求7所述的靶向外泌体在制备抗肿瘤药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210708212.XA CN115304656A (zh) | 2022-06-22 | 2022-06-22 | 一种特异性激活细胞泛凋亡途径的囊泡药物构建及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210708212.XA CN115304656A (zh) | 2022-06-22 | 2022-06-22 | 一种特异性激活细胞泛凋亡途径的囊泡药物构建及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115304656A true CN115304656A (zh) | 2022-11-08 |
Family
ID=83855738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210708212.XA Pending CN115304656A (zh) | 2022-06-22 | 2022-06-22 | 一种特异性激活细胞泛凋亡途径的囊泡药物构建及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115304656A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112672736A (zh) * | 2018-06-29 | 2021-04-16 | 国家儿童医院研究所 | 用于介导eps的组合物和方法 |
CN112912110A (zh) * | 2018-06-12 | 2021-06-04 | 安吉克公司 | 抗体-寡核苷酸缀合物 |
CN113453694A (zh) * | 2019-01-22 | 2021-09-28 | 科罗生物公司 | Rna编辑的寡核苷酸及其用途 |
-
2022
- 2022-06-22 CN CN202210708212.XA patent/CN115304656A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112912110A (zh) * | 2018-06-12 | 2021-06-04 | 安吉克公司 | 抗体-寡核苷酸缀合物 |
CN112672736A (zh) * | 2018-06-29 | 2021-04-16 | 国家儿童医院研究所 | 用于介导eps的组合物和方法 |
CN113453694A (zh) * | 2019-01-22 | 2021-09-28 | 科罗生物公司 | Rna编辑的寡核苷酸及其用途 |
Non-Patent Citations (3)
Title |
---|
ACHIM MOLLER,等: "Bromination Stabilizes Poly( dG-dC) in the Z-DNA Form under Low-Salt Conditions", 《BIOCHEMISTRY》, vol. 23, no. 1, 31 December 1984 (1984-12-31), pages 54 - 62 * |
PRITI KRISHNA,等: "Interaction of RecA Protein with Acidic Phospholipids Inhibits DNA-Binding Activity of RecA", 《JOURNALOFBACTERIOLOGY》, vol. 172, no. 11, 30 November 1990 (1990-11-30), pages 6452 - 6458, XP008058361 * |
SIDDHESH D. PATIL,等: "Biophysical characterization of anionic lipoplexes", 《BIOCHIMICA ET BIOPHYSICA ACTA》, vol. 1711, 31 March 2005 (2005-03-31), pages 1 - 11 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Huang et al. | Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer | |
Wang et al. | mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma | |
US20220267731A1 (en) | Anti-robo1 car-t cell, and preparation and application thereof | |
Goodwin et al. | Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival | |
Kinoh et al. | Translational nanomedicine boosts anti-PD1 therapy to eradicate orthotopic PTEN-negative glioblastoma | |
US20200323772A1 (en) | Treatment of inflammatory disease using ingestible device to release immune modulator | |
JP6294510B2 (ja) | 腫瘍特異性標的投与の薬物キャリア及びその応用 | |
CN107980004A (zh) | 用于医治疾病的外泌体的用途 | |
CN109071597A (zh) | 治疗性膜囊泡 | |
KR20210040948A (ko) | 단핵구 및 대식세포의 염증성 표현형을 조절하기 위한 조성물 및 방법, 그리고 이의 면역요법 용도 | |
JP6933379B2 (ja) | 転移を低減するための方法および組成物 | |
Choi et al. | Targeted delivery of exosomes armed with anti-cancer therapeutics | |
Rousseau et al. | Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models | |
Zhao et al. | A new tandem peptide modified liposomal doxorubicin for tumor “ecological therapy” | |
Qian et al. | Dual-aptamer-engineered M1 macrophage with enhanced specific targeting and checkpoint blocking for solid-tumor immunotherapy | |
KR20230087570A (ko) | PAN-RAS mRNA 암 백신 | |
CN111479557A (zh) | 用于使用外排体相关基因编辑来治疗癌症的方法和组合物 | |
CN110157686B (zh) | 一种免疫检查点激活免疫共刺激的复制型溶瘤腺病毒及其构建方法和应用 | |
Wang et al. | Emerging extracellular vesicle-based carriers for glioblastoma diagnosis and therapy | |
Saha et al. | Combating Established Mouse Glioblastoma through Nicotinylated‐Liposomes‐Mediated Targeted Chemotherapy in Combination with Dendritic‐Cell‐Based Genetic Immunization | |
CN115252582A (zh) | 红细胞膜杂合pH脂质体包被溶瘤病毒制剂的制备及应用 | |
Yang et al. | Black phosphorus nanosheets assist nanoerythrosomes for efficient mRNA vaccine delivery and Immune Activation | |
IT201900012540A1 (it) | Inibitori di CHI3L1 e loro usi | |
CN115025223A (zh) | 一种用于激活休眠肿瘤细胞的setd4蛋白抑制剂的投递蛋白 | |
CN115304656A (zh) | 一种特异性激活细胞泛凋亡途径的囊泡药物构建及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |